JPWO2020219848A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219848A5 JPWO2020219848A5 JP2021563352A JP2021563352A JPWO2020219848A5 JP WO2020219848 A5 JPWO2020219848 A5 JP WO2020219848A5 JP 2021563352 A JP2021563352 A JP 2021563352A JP 2021563352 A JP2021563352 A JP 2021563352A JP WO2020219848 A5 JPWO2020219848 A5 JP WO2020219848A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polynucleotide
- cell
- vector
- cells
- engineered immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839455P | 2019-04-26 | 2019-04-26 | |
| US62/839,455 | 2019-04-26 | ||
| US202063005041P | 2020-04-03 | 2020-04-03 | |
| US63/005,041 | 2020-04-03 | ||
| PCT/US2020/029775 WO2020219848A1 (en) | 2019-04-26 | 2020-04-24 | Rituximab-resistant chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532996A JP2022532996A (ja) | 2022-07-21 |
| JPWO2020219848A5 true JPWO2020219848A5 (ru) | 2023-04-28 |
Family
ID=70847489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563352A Pending JP2022532996A (ja) | 2019-04-26 | 2020-04-24 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11896617B2 (ru) |
| EP (2) | EP4295851A3 (ru) |
| JP (1) | JP2022532996A (ru) |
| KR (1) | KR20220004076A (ru) |
| CN (1) | CN113728001A (ru) |
| AU (1) | AU2020263495A1 (ru) |
| BR (1) | BR112021021178A2 (ru) |
| CA (1) | CA3134308A1 (ru) |
| CO (1) | CO2021014121A2 (ru) |
| DK (1) | DK3959235T3 (ru) |
| ES (1) | ES2961314T3 (ru) |
| FI (1) | FI3959235T3 (ru) |
| IL (1) | IL287487A (ru) |
| MX (1) | MX2021012820A (ru) |
| PE (1) | PE20212369A1 (ru) |
| SG (1) | SG11202111031RA (ru) |
| TW (1) | TW202106704A (ru) |
| WO (1) | WO2020219848A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117396607A (zh) | 2020-12-30 | 2024-01-12 | 阿劳诺斯治疗公司 | 包含多顺反子表达盒的重组载体及其使用方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| NZ532060A (en) | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2013176916A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| CN105431532B (zh) | 2013-05-13 | 2021-04-06 | 瑟勒提斯公司 | Cd19特异性嵌合抗原受体及其用途 |
| DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| CA2937938A1 (en) | 2014-02-04 | 2015-08-13 | Kite Pharma, Inc. | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| JP6868554B2 (ja) * | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| US11014989B2 (en) | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
| GB201518792D0 (en) * | 2015-10-23 | 2015-12-09 | Univ Manchester | Production of proteins |
| WO2017103613A1 (en) | 2015-12-18 | 2017-06-22 | Ucl Business Plc | Treatment |
| EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| GB201609597D0 (en) | 2016-06-01 | 2016-07-13 | Univ Sheffield | Therapy |
| SG11201907922PA (en) * | 2017-03-03 | 2019-09-27 | Obsidian Therapeutics Inc | Cd19 compositions and methods for immunotherapy |
| EP3784785A4 (en) | 2018-04-23 | 2022-02-16 | Duke University | DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION |
| SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
-
2020
- 2020-04-24 PE PE2021001764A patent/PE20212369A1/es unknown
- 2020-04-24 SG SG11202111031RA patent/SG11202111031RA/en unknown
- 2020-04-24 ES ES20728258T patent/ES2961314T3/es active Active
- 2020-04-24 JP JP2021563352A patent/JP2022532996A/ja active Pending
- 2020-04-24 AU AU2020263495A patent/AU2020263495A1/en active Pending
- 2020-04-24 EP EP23186544.5A patent/EP4295851A3/en active Pending
- 2020-04-24 MX MX2021012820A patent/MX2021012820A/es unknown
- 2020-04-24 TW TW109113823A patent/TW202106704A/zh unknown
- 2020-04-24 CA CA3134308A patent/CA3134308A1/en active Pending
- 2020-04-24 EP EP20728258.3A patent/EP3959235B1/en active Active
- 2020-04-24 US US16/857,573 patent/US11896617B2/en active Active
- 2020-04-24 CN CN202080031593.1A patent/CN113728001A/zh active Pending
- 2020-04-24 FI FIEP20728258.3T patent/FI3959235T3/fi active
- 2020-04-24 KR KR1020217036085A patent/KR20220004076A/ko unknown
- 2020-04-24 DK DK20728258.3T patent/DK3959235T3/da active
- 2020-04-24 BR BR112021021178A patent/BR112021021178A2/pt unknown
- 2020-04-24 WO PCT/US2020/029775 patent/WO2020219848A1/en active Application Filing
-
2021
- 2021-10-21 IL IL287487A patent/IL287487A/en unknown
- 2021-10-22 CO CONC2021/0014121A patent/CO2021014121A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11160833B2 (en) | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 | |
| KR102618231B1 (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| CN108715859B (zh) | 靶向cd22的嵌合抗原受体及其应用 | |
| Tsuji et al. | Generation of tumor-specific, HLA class I–restricted human Th1 and Tc1 cells by cell engineering with tumor peptide–specific T-cell receptor genes | |
| CN112638947B (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| JP2023085527A5 (ru) | ||
| JP2017537919A5 (ru) | ||
| CN110944652A (zh) | T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途 | |
| AU2019307905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| CN115698081A (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| EP3844184A1 (en) | Activation of antigen presenting cells and methods for using the same | |
| CA3215528A1 (en) | Chimeric antigen receptors and modified cells comprising the same | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| EP3914719A1 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| JPWO2020219848A5 (ru) | ||
| FI3959235T3 (fi) | Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö | |
| RU2021134337A (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
| Li et al. | Genetically Modified T-cells Affinity to Tumor Cells-Development of Adoptive T-cell Immunotherapy | |
| WO2020190936A1 (en) | Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor | |
| JP2015092865A (ja) | ヒト化抗ｃｄ２０キメラ抗原レセプター | |
| NL2030990B1 (en) | T cell receptors directed against jchain and uses thereof | |
| JPWO2020087116A5 (ru) | ||
| CN117683136A (zh) | 嵌合抗原受体、慢病毒、修饰nk细胞及其应用 | |
| WO2023232745A1 (en) | Anti-idiotype antibodies and uses thereof | |
| CA3198363A1 (en) | Methods and compositions comprising pd1 chimeric polypeptides |